ERBB2 and breast cancer: As for the major BC clinical subtypes, the proportions of HER2+/HR–, HER2–/HR+, TNBC, and HER+/HR+ subtypes were 3.6%, 61.9%, 8.4%, and 6.2% of all BC cases in our study, respectively.